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Background: Lowered costs of genomic sequencing facilitate analysing large segments of genetic 
data. Ethical debate has focused on whether and what kind of incidental or secondary findings (SFs) 
to report, and how to obtain valid informed consent. However, people’s support needs after 
receiving SFs have received less attention. We explored Finnish adults’ perspectives on reporting 
genetic SFs. 
 
Materials and methods: In this qualitative study which included four focus group discussions 
(N=23) we used four vignette letters, each reporting a genetic SF predisposing to a different 
disease: familial hypercholesterolemia, long QT syndrome, Lynch syndrome and Li–Fraumeni 
syndrome. Transcribed focus group discussions were analysed using inductive thematic analysis. 
 
Results: Major themes were immediate shock, dealing with worry and heightened risk, fear of being 
left alone to deal with SFs, disclosing to family and identified support needs. Despite their 
willingness to receive SFs, participants were concerned about being left alone to deal with them. 
Empathetic expert support and timely access to preventive care were seen as essential to coping 
with shock and worry, and disclosing SFs to family.  
 
Conclusions: Discussion around SFs needs to concern not only which findings to report, but also 
how healthcare systems need to prepare for providing timely access to preventive care and support 
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Recent advances in genetics and lowered costs of whole genome/exome sequencing facilitate 
analysing large segments of genetic data. This raises the possibility of generating different types of 
findings unrelated to the original research question or clinical investigation. These additional 
findings are commonly called incidental findings, but this term has been criticized since their 
identification requires active analytical effort (Shkedi-Rafid et al., 2014). In this paper we use the 
term secondary findings (SFs) (Kalia et al., 2016) to cover both truly incidental and actively sought 
findings that are unrelated to the original purpose of genomic sequencing. Amongst other types, SFs 
can be single variants suggesting high risk for heritable diseases, including certain cancers and 
cardiovascular diseases. 
There has been intense ethical debate on the reporting back of genetic SFs. Discussion has focused 
upon differing ethical principles guiding research and clinical practice (Hallowell et al., 2015), 
uncertainty inherent in genetic risk information (Newson et al., 2016), whether and what kind of 
SFs to report back (Christenhusz et al., 2013), and how to obtain valid informed consent (Mackley 
et al., 2016). Consensus is emerging that scientifically robust, analytically valid, and clinically 
actionable findings should be reported back to research participants who have consented to receive 
them (Knoppers et al., 2015; Wolf, 2013), and this reflects lay people’s preferences (Bollinger et 
al., 2012; Daack-Hirsch et al., 2013; Haukkala et al., 2013; Loud et al., 2016; Ormondroyd et al., 
2007). The American College of Medical Genetics and Genomics (ACMG) recommends looking 
for and returning SFs  in 59 genes during clinical sequencing (Kalia et al., 2016), and the European 
Society of Human Genetics recommends involving public perspectives when incorporating genome 
sequencing into healthcare (van El et al., 2013). 
Most research participants wish to receive individual genetic research results and SFs (Facio et al., 
2013; Loud et al., 2016), particularly if they are treatable or preventable. A few studies have looked 
at reactions to receiving genetic findings which emerge during research studies (Hallowell et al., 
2013; Haukkala et al., 2013; Lewis et al., 2016; McBride et al., 2016; Ormondroyd et al., 2007; 
Sanderson et al., 2017). In a recent Finnish study (Haukkala et al., 2013), biobank participants 
received, via letter, unexpected genetic results for long QT syndrome (LQTS) – a treatable, but 
potentially fatal, cardiac arrhythmia. Most of the 17 participants were positive about receiving this 
information, particularly as preventative measures were available.  Likewise ClinSeq participants 
who had opted to receive SFs via counselling – primarily related to cancer, cardiomyopathy, LQTS 
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and familial hypercholesterolemia (FH) – perceived the information as useful for personal and 
family health after receiving SFs (Lewis et al., 2016). Other studies have observed more ambivalent 
responses to receiving unexpected genetic risk information (Hallowell et al., 2013; Ormondroyd et 
al., 2007). While there is a growing literature on individuals’ reactions to receiving SFs, the types of 
support that people need after receiving SFs has received less empirical attention. In addition, the 
ways in which people expect healthcare systems to respond to these needs is largely unexplored.  
Genetic risk information is received in different individual, social and cultural contexts. McBride et 
al.’s (McBride et al., 2016) qualitative study explored how research participants and their relatives 
reacted to receiving a letter that revealed a variant linked to Li–Fraumeni syndrome (LFS), which 
predisposes to several cancers. Their results emphasize the importance of timing and individuals’ 
life situation when receiving unanticipated findings. For example, in the presence of a newly 
diagnosed cancer in the family individuals said they were less able to process genetic risk 
information (McBride et al., 2016). We argue that besides personal life situation, concerns and 
needs around receiving SFs may be shaped by wider sociocultural structures, such as availability of 
social welfare and types of healthcare systems, and cultural ideals (Press et al., 2000). Arguably, 
people’s contextualized needs and concerns following the receipt of SFs need to be better 
understood when designing clinical and research procedures for disclosing this type of information. 
The aim of our study was to explore Finnish adults’ perspectives on the reporting of genetic SFs via 
letter, more specifically high risk single variants linked to serious but actionable diseases. It extends 
previous literature by exploring not only people’s willingness to receive SFs, but also their potential 
support needs and concerns following the receipt of SFs in a hypothetical situation. 
Materials and Methods 
To explore people’s concerns and support needs we used a qualitative vignette study design, which 
employed focus group discussions (Barbour, 2008). Members of the public were recruited by the 
Helsinki area Metro newspaper, which ran an advertisement about the study on three days in April–
May 2016. The advertisement headed ‘How should hereditary risk information be delivered’, called 
for 18–64-year-old volunteers (compensation: two cinema tickets). There were no exclusion 
criteria, but the participants needed to be able to speak Finnish. Interested volunteers (N=32) were 
e-mailed an online survey with consent form, demographic questionnaire, and open-ended writing 
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task. The writing task was completed by 29 adults, of whom 23 attended focus group discussions. 
This paper only reports data from focus group discussions. 
The writing task asked participants to read a vignette letter (Table 1), which revealed a genetic SF 
generated during a clinical examination, and imagine themselves receiving this letter in real life. 
Four versions of the letter were constructed and these were randomly assigned. Each reported a 
variant linked to either familial hypercholesterolemia (FH), long QT syndrome (LQTS), Li–
Fraumeni syndrome (LFS), or Lynch syndrome (LS). We chose these diseases since they are all on 
the ACMG list of variants to be reported back following WGS (Kalia et al., 2016), and we had 
previous experience of disclosing incidental LQTS findings (Haukkala et al., 2013), and of directly 
contacting LS families for genetic testing (Aktan-Collan et al., 2007). To vary the diseases in terms 
of their treatability, we chose another cardiovascular disease FH, which is relatively common, and 
easily treatable, although is undertreated in Finland (Lahtinen et al., 2015), and another cancer 
syndrome LFS, which has fewer prevention possibilities (Schneider et al., 1993). Table 2 describes 
the diseases and their treatment options (this table was not given to the study participants). 
After reading one of the four letters, participants (N=29) were asked to write down their initial 
thoughts upon receiving the letter, and describe what they would do in this hypothetical situation 
(Table 1). Between 0–7 days later, 23 participants attended focus group discussions (N=4; indicated 
below as A–D); these contained 4–7 participants each. In each session, the participants discussed 
one letter on cancer (either LS or LFS) and one letter on cardiovascular disease (either FH or 
LQTS), one of which each participant had read during the earlier writing task. MV and KA-C led 
and moderated the discussions using a topic guide, which focused upon: first reactions to the letter, 
perceptions of disease and risk, searching for information, family, recommendations for 
implementation, and consent. Participants were encouraged to discuss the topic broadly. Sessions 
lasted between 94–125 min (mean 114). Approximately 45 min into the discussion, KA-C, a 
medical doctor, introduced a slide show (14–32 min, 13 slides), providing further information on 
the two diseases under discussion, and answered questions about these diseases. We started the 
discussions before presenting more information to first discuss participants’ initial reactions to their 
hypothetical results. The aim was to mimic a realistic process, in which first impressions might 
change after receiving more information on the condition via genetic counseling.  
Focus group discussions were transcribed verbatim and analysed using inductive thematic analysis 
(Braun and Clarke, 2006). The analysis aimed to capture implicitly expressed meanings in addition 
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to explicitly stated opinions (Braun and Clarke, 2006) on the following: What are lay people’s 
concerns and needs related to receiving genetic SFs linked to serious but actionable conditions? MV 
coded the transcripts and discussed the emerging codes and their grouping into larger themes at 
length with KA-C, who had co-facilitated the focus groups and thoroughly familiarized herself with 
the transcripts. KA-C agreed with MV's interpretation of the data. The overall thematic structure 
was further discussed in a number of data discussion meetings that included MV, KA-C and NH. 
Chosen data extracts were translated into English during manuscript writing. 
Results 
Focus group participants (N=23) were between 20–64 years old, primarily middle-aged (mean age 
50; 19/23 over 40) and female (21/23). Their educational and professional backgrounds were 
diverse: 9/23 had a university degree, and 3/23 reported working in the healthcare sector (nurses, 
personal assistants). Approximately half of participants (N=12) had children. In focus groups, 
several participants spontaneously brought up a family history of cancer, heart disease or high 
cholesterol; one participant was waiting for a genetic test for a heart related condition (other than 
FH or LQTS).  
The study scenario (Table 1) assumed that the participant, hypothetically, had already given their 
consent to receiving SFs. The study participants approached the topic from this perspective, and 
discussed the aftermath of receiving SFs rather than whether or not they would like to receive them. 
In general, participants were in favour of receiving SFs, but some had mixed feelings. Particularly 
towards the end of the lengthy focus group discussions, participants tended to express more 
ambivalence, seemingly because they were slightly overwhelmed by all the complexities involved. 
Presenting more information on the diseases in the midst of the session did not drastically change 
the course of discussion. However, participants suggested that some modifications to the vignette 
letters could prevent misunderstandings. For example, they suggested effectiveness of preventive 
measures should be emphasized, in order to reduce distress and potential avoidant reactions. Also, 
participants discussed whether and how commonness or uncommonness of the syndrome might 
play a role in how it could be managed in the healthcare system. With regard to potential concerns 
and needs after receiving SFs, we identified five major themes within focus group discussions: 
immediate shock, dealing with worry and heightened risk, fear of being left alone to deal with SFs, 
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disclosing to family and identified support needs. These contained a number of subthemes as 
outlined below. 
Immediate shock 
Negotiating the level of shock was participants’ first reaction to reading the letter. Many 
participants described receiving the letter as a ‘surprise’, ‘shock’ or ‘bomb’ (e.g. below, 
A7=seventh speaker of focus group A), although a minority said they ‘did not take it very seriously’ 
(D1). In particular, participants commented that receiving SFs could be difficult for certain groups: 
younger people, females, and those who tend to worry in general. 
Despite acknowledging that SFs could be shocking, participants disapproved of worrying too much 
about one’s health. To resolve this conflict of being shocked, but also wanting to appear reasonable 
and capable of coping with risk information, participants defended and normalized their own 
(hypothetical) emotional reactions to the letter by emphasizing the severity of the disease.  
A7: but in any case this is like a bomb to anyone [A2: yeah!] there’s no such person to 
whom this is not like a bomb. 
However, focus group participants also implied that one was expected to manage the situation 
eventually. Participants actively distanced themselves from ‘those people’ who would panic upon 
reading this type of letter. Being rational and open to receiving risk information were considered 
desirable traits, instead of ‘panicking’ or ‘sticking one’s head in the sand’ (D3), i.e. choosing to live 
in denial of one’s risk status. The following interchange shows how D2 and D3 distanced 
themselves from ‘those’ irrational, weak or fearful people who tend to panic.  
D2: but there are people who don’t need but the zero point zero something per cent 
risk and still the anxiety, the fear hits them and they collapse, you know that kind of 
people 
D3: on my part I certainly would think about the odds  
D2: but that indicates courage. Then there are those who start to be fearful straight 
away before there is really anything at all 
D3: yeah, but I just wanted to make clear, that I would not like push it away, like 
because of fear, but instead like through reason 
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Discussions such as these suggest that in the aftermath of receiving SFs there is more than the shock 
to deal with. Individuals may experience pressure to manage their emotional reactions in a socially 
desirable way, to appear strong, rational, and capable of dealing with bad news. Focus group 
participants made no explicit statements that overtly displaying emotional distress would be 
shameful. Yet, since participants actively attempted to avoid falling into the category of ‘those 
people’ who are not able to handle their emotions, an implicitly felt threat of shame over one’s 
emotionality was apparent in their responses. Finally, some participants recognized that receiving 
SFs could be seen as a positive event; as a ‘wakeup call’, as it might remind one to ‘live one’s life 
to the fullest’ (A6). 
Dealing with worry and heightened risk 
Participants also identified the possibility that receiving SFs could generate enduring anxiety and  
discussed how receiving SFs could evoke ‘stress’, a ‘placebo effect’, or ‘energy’ that might in turn 
trigger the genetic risk and cause the illness. 
A6: if we learn about a possibility to develop some illness, and then we give it both 
our own energy and our relatives’ worry energy, and start to like dwell on it (--) so 
are you like actively activating the gene 
Dealing with worry and heightened risk was seen as a threat to holistic wellbeing. Indeed, some 
disapproval was voiced about vigorous attempts to control health risks:  
A7: everything has to be so controlled (--) and then you just hysterically follow 
[guidelines of authorities] (--) like common sense is all lost [these days] 
In sum, participants described how receiving a letter suggesting an unanticipated inherited risk for 
cancer or cardiovascular disease was emotionally confronting and had the potential to cause 
ongoing distress. This distress arose partially because they were afraid they might be left on their 
own to deal with this information. 
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Fear of being left alone to deal with secondary findings 
Participants’ overarching concern was that it would be distressing to be left on their own to make 
sense of the SF and cope with the shock and worry. Concerns about being left alone to deal with 
SFs were related to a) immediate situation of receiving the letter, b) one’s personal life situation, 
and c) structure and equity of healthcare system. 
Immediate situation 
Many participants felt that being left alone to cope with ‘horror scenarios’ that SFs might evoke was 
unacceptable. While some said they were happy to receive the information in a letter, many said 
they would prefer to receive SFs in person or by phone.  
D5: No letter! This is somehow so sterile and you collapse after this. At first you will 
be like, ‘Aha, yeah ok’, but when you start going through it in your head, like ‘Help’, 
you panic 
While participants were pleased that the vignette letters provided (hypothetical) contact details 
suggesting where they might access further information and support, some participants worried 
about finding the time to call and discuss this issue in the midst of a busy life.  
Personal life situation 
One’s previous experiences, current life situation, and future prospects were all seen to affect the 
meaning of the SFs, and the extent to which one would feel threatened by this information. Again, 
younger people were perceived as more vulnerable because it was reasoned that receiving SFs at a 
younger age could complicate future life decisions and isolate one from peers. 
D2: how on earth would a [15-year-old] person who wants to be like everyone else 
bear having this kind of very rare thing [risk for LFS], so it would be even worse, at a 
certain age 
At older ages, the threat of illness was seen as more commonplace, less stigmatizing, and hence not 
as threatening to social relations like friendships, romantic relationships and family planning. 
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Structure and equity of healthcare system 
Fear of being left alone to deal with SFs was also influenced by views of the wider societal 
structure. Participants explicitly linked the acceptability of reporting SFs to the stability and 
justness of healthcare system and society in general. Trust towards society, science, and healthcare 
appeared important for feeling safe and cared for after receiving SFs.  
A7: we have exceedingly skilled clinical professionals, and our doctors and research 
and everything are really top-notch, like the care one receives in Finland is so good 
so I definitely wouldn’t be worried one bit 
It was argued that in an equal, stable and just society that ensures access to treatment and care, 
disclosing SFs would be more acceptable compared to an unequal, poorly structured society where 
not everyone has access to proper healthcare. In the latter case, information about SFs was 
perceived as potentially benefiting those who are well-off, and further harming the disadvantaged. 
Ensuring a sense of safety and being taken care of, and simultaneously supporting individual 
autonomy were emphasized. 
B1: if the society is like just and equal, then people might be more ready to receive the 
[SF] information, because they would feel they are safe (pause) but if it’s a very 
unequal society, and everything is like going in a bad way (pause) then it could be, it’s 
hard to say, then everyone acts more (pause) from their own stances. Some flush their 
lives down the toilet and some [other interviewee: pull themselves together] yeah, pull 
themselves together 
In sum, being left alone to deal with SFs was a major concern in several ways. Uncertainty about 
who they could discuss SFs with added to such concerns, indeed, seeking support from family 
members was considered problematic since the information also concerned them. 
Disclosing to family  
Participants were concerned about a potential lack of support when it came to disclosing SFs to 
their relatives. Concern for the family included worries about family members’ health, and also the 
worry that disclosure could harm family relations. In addition, participants expressed concerns since 
they perceived conflicting responsibilities to both disclose SFs and to protect family from worry. 
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Disclosing SFs was described as a difficult task for a professional, let alone a lay person who lacked 
expertise in genetics, medicine, or communication. Participants felt a responsibility to disclose 
information to family members, but also a responsibility to support their relatives following 
disclosure. 
C4: it would be very hard as a lay person to inform another person about this kind of 
possibility to a serious hereditary illness, because you don’t have all the information, 
(--) you really have no answers to questions that could arise in that situation, so it 
would be quite a scary situation, I mean informing others, how to then do it so that the 
other one doesn’t panic altogether 
Parents’ responsibility to be able to take care of and support their children was particularly 
emphasized. Participants implied that in these situations the parents’ own emotions and needs were 
no longer the focus, but instead their role as a responsible caregiver. 
D5: the parent has to be able to like be strong then, and there for the child and 
listening and, and like safe 
Participants acknowledged that whatever one might perceive as the right time and way to disclose 
the information to children in principle, in practice, it might be difficult to keep SFs secret. On the 
one hand, children and young people were seen as vulnerable and therefore, in need of protection 
from worry about risk. On the other hand, it was argued that ‘growing up knowing’ about risk might 
enable children to avoid the shock of unexpectedly finding out this information later: 
A2: That way it will not startle you if everything is thought through beforehand, that 
you might get it from [this or that side of the family] [A3 and A4 agree] discussed 
beforehand around the kitchen table so even if grandchildren are there to hear it, it 
will not be striking (laughter) 
Identified support needs  
To cope with shock and worry, and to be able to make the best possible decisions for themselves 
and their relatives, participants said they needed timely access to expert support, including:  
information, access to care and empathetic communication. 
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Information and access to care 
Reliable and reassuring information was seen as enabling individuals to cope with the initial shock 
of receiving SFs. Rapid access to reliable information was particularly emphasized since ‘these days 
you can find all kinds of [scary and unreliable] things on the internet’ (D1), which could easily be 
misinterpreted. Timely information about preventive methods and cures was seen as a means to 
tackle uncertainty and fear of the unknown, to gain control of the situation. 
A5: at first you panic, but the more you get to know about the matter, the easier it 
gets. And then if you know, like (pause) how it’s treated. To me that’s always the most 
important, that I know how to go forward, and how I can survive this (pause) so, I 
think this letter is very good. And the fact that you can contact, probably I would 
contact them (pause) so (pause) I would like to discuss it further with an expert  
However, perceptions of reliable information sources varied and covered more than professional 
knowledge. Some participants wished for peer support to access emotional support and to gain 
relevant information that ‘a doctor won’t tell’ (A5). In addition, one participant brought up the 
possibility of seeking information on alternative treatments, since she did not ‘trust chemical, 
artificial medicine unconditionally’ (C4). Other participants had a practical approach, and felt that 
the possibility to do something immediately would relieve anxiety. This is why they endorsed 
prompt and detailed advice on what to do and whom to contact. 
C2: I don’t necessarily understand so much about these genes, but I also wouldn’t 
have needed, that they would have explained it all through, (--) to me there was 
enough information and advice what to do and so on 
Empathetic communication 
In addition to a need for knowledge and concerns about access to care, the need for expert support 
was linked to an emotional need to be taken care of and treated in a respectful manner, which 
promotes feelings of safety and being valued. These needs were clearly connected to previous 
hurtful experiences of healthcare. Needs for information and emotional support were tightly 
intertwined; the content of information and communicating it in a respectful, sensitive manner were 
considered equally important. Experience of being taken care of was perceived as strongly 
supporting coping with SFs. 
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D4: it has an enormous impact, what kind of (pause) conversation you can create 
then, and plan for further care, that gets you through everything 
Participants emphasized that considerate and easy to understand wordings in feedback letters or 
possible other written information materials were essential. Nevertheless, they emphasised that no 
matter how informative and reassuring such materials might be, the possibility for human contact 
would be crucial after receiving SFs, either in person or by phone: 
D5: someone has to call then, and have time [to discuss the SF], I mean at least call 
or tell you face to face (--) 
D2: And this letter is very well formulated anyway, there is nothing wrong with that. 
You can’t really put it any more nicely [D5: yeah you can’t really], that type of 
information 
Discussion 
We examined Finnish adults’ potential concerns and needs related to receiving serious but 
actionable genetic SFs via letter. Despite a general positive attitude towards receiving SFs, concern 
about being left alone to deal with this information was widely expressed. Empathetic expert 
support and prompt access to preventive care and treatment were seen as essential to coping with 
immediate shock, heightened risk and potential prolonged worry, as well as to being able to disclose 
SFs to family in an appropriate way. While the results of the current study support previous findings 
that stress the importance of practical guidance (Daack-Hirsch et al., 2013) and timely opportunities 
for  retesting (Haukkala et al., 2013), they provide new insight into how contextual factors, such as 
the structure of healthcare system, may shape how people expect the healthcare to respond to their 
needs for treatment and support after receipt of SFs. 
Access to empathetic expert support and further care were considered as means to cope with 
emotional distress caused by the SF’s implications for oneself and family members. Participants 
depicted shock as an understandable first reaction to receiving SFs that could be overcome if, and 
only if, appropriate support and information are available. There is some evidence that distress 
following receipt of information on LS variants or BRCA variants (linked to breast and ovarian 
cancers) eases after a few weeks (Aktan-Collan et al., 2013; van Oostrom et al., 2003). However, 
when family members of Australian Ovarian Cancer Study participants received an unexpected 
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letter stating that a BRCA variant had been detected in their family, they described themselves as 
more distressed than the original research participants (Hallowell et al., 2013). Further research is 
needed to examine whether unexpectedness and potential unfamiliarity with the diseases associated 
with the SFs might cause more enduring distress. Moreover, the subtle threat of shame about overly 
emotional reactions that was implied in our participants’ responses, might also discourage 
individuals from expressing negative reactions in research interviews or clinical encounters. This 
observation  may be culturally specific as stubborn perseverance in the face of difficulties is 
generally highly valued in Finnish culture (Lahti, 2013). Yet, the potential for similar pressure to 
appear strong and capable should be taken into account also in other cultures that value individual 
agency in managing one’s life. 
Similarly, access to care and clear clinical procedures and processes were seen as crucial to long 
term coping with SFs. This finding is in line with previous studies’ conclusions that people wish 
information about SFs to be accompanied with a practical plan (Daack-Hirsch et al., 2013), and that 
prolonged re-test procedures may cause distress (Haukkala et al., 2013). Professionals have 
expressed reluctance about returning SFs, due to lack of comprehensive practice framework, 
uncertainty in interpreting genomic results, the need to update consent practices, and the fact that 
the finding concerns not only the individual but the whole family (Gourna, 2016). Our results 
endorse these reservations, suggesting that those who receive SFs expect timely support and clear 
procedures.  
Expert support was also seen as needed to help with disclosing SFs to family. A similar wish was 
identified in a previous Finnish study within LS families (Aktan-Collan et al., 2011). Our 
participants considered delivering SFs a demanding task even for a professional, due to dual 
demands of expertise and empathy. Still, in line with previous research (Hallowell et al., 2003; 
Vavolizza et al., 2015), they felt responsible for disclosing the information about genetics to their 
family. At the same time, they felt responsible for coming to terms with the IF on their own at first, 
so that they would be able to support others. Parents’ responsibility to take care of their children 
was particularly emphasized, to the extent that it could even overwhelm parents’ own needs. These 
results shed light to previous contradictory observations that suggest that perceived responsibility 
for one’s children may encourage willingness (Christenhusz et al., 2014), ambivalent feelings 
(Haukkala et al., 2013; Wright et al., 2014), or reluctance towards receiving genetic research results 
(Richards et al., 2003). In addition to parents, receiving SFs was perceived as distressing for young 
people, whose friendships and family planning receiving SFs might complicate. Overall, our results 
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emphasize McBride et al.’s (McBride et al., 2016) remarks on the importance of an individual’s life 
situation when receiving SFs.  
If and when international guidelines for managing SFs are formulated, it should be noted that, in 
practice, such guidelines will be applied in nuanced societal and cultural contexts, in which 
responsibilities of different actors may be emphasized differently. Results of the current study 
highlight a need to evaluate the practices of reporting SFs in the context of a publically funded 
healthcare system. Disclosing SFs is never an isolated act but contextualized within the relationship 
of the disclosing institution/person and the patient/research participant/family member. Consistent 
with previous literature (Daack-Hirsch et al., 2013), current participants perceived managing SFs as 
a shared responsibility between healthcare professionals and patients. They implied that whoever 
discloses the information is, to some degree, responsible for taking care of the recipient of the 
information. The nature and degree of perceived responsibility appears to stem from the relationship 
between the disclosing institution/person and the recipient. Not only were parents seen as 
responsible for their children, but also the healthcare system was seen as responsible to provide 
support and further care for the families who received this information. Our study participants 
expected to receive support and equal access to treatment for everyone after receipt of SFs, but were 
concerned whether there would be resources to manage this appropriately. These expectations and 
concerns reflect the Finnish context where tax-funded public healthcare is available and, in general, 
takes some responsibility for citizens’ health and wellbeing. We hypothesise that in countries 
without public healthcare systems, people might expect and seek support from other sources. 
Since disclosure happens within a particular relationship, the act and way of disclosure may also 
influence that relationship. In line with previous research (Vavolizza et al., 2015), our study 
participants identified potential for strengthened family ties, but also isolation after disclosing SFs 
to family members. Similarly, disclosing SFs may affect relationships between healthcare 
system/research and the patient/participant. The widely expressed fear of being left alone to 
understand and deal with the emotional and practical sequelae of SFs suggests that adverse 
reactions and distrust towards research and healthcare may arise, if the ways of reporting SFs and 
referral for treatment/prevention are perceived as disrespectful, disorganized, or unequal. 
Communication and collaboration between research and clinics should be attended to (Lohn et al., 
2014). Indeed, we suggest that societies with public healthcare systems need to allocate resources to 
psychosocial support and preventive treatment when formulating policies for disclosing SFs. This is 
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important also because appropriate support is likely to encourage risk communication within 
families (Gaff et al., 2007). 
Methodological considerations 
Participants in this study were asked to imagine a situation in which they received serious, but 
actionable, genetic SFs via letter. The use of hypothetical scenarios has been criticized, since 
imagined accounts do not necessarily match actual behaviour (Persky et al., 2007). In response, we 
argue that the vignette approach of this study had some significant advantages. We assume 
participants were not as distressed as they might be in a real situation, and thus, these focus group 
discussions offered them a safe space to explore a broad variety of points of views on the topic. In 
addition, the use of hypothetical scenarios meant that we could interview people only days after 
they ‘received’ SFs. 
Some previous studies of the feedback of SFs to research participants during a counselling session 
(Lewis et al., 2016) or via letter (Haukkala et al., 2013) have reported almost exclusively neutral or 
positive reactions. A longer time between receiving SFs and interviews could explain this 
difference, but it should be noted that in those previous studies, only 31/46 and 17/27 invited 
individuals, respectively, participated in the studies. Since it is challenging to recruit interviewees 
who do not wish to receive genetic risk information in the first place (Richards et al., 2003), it is 
possible that those who experience more distress avoid participating in studies after receiving SFs. 
Further research is needed to explore whether adverse reactions to receiving SFs discourages 
participation, which might bias research on reactions. 
The scenario presented in this study concerned reporting SFs in clinical practice. Clinical patients 
and genetic research participants go through genome sequencing for different reasons and with 
different expectations (Sanderson et al., 2015). Similarly, people’s expectations for support after 
receiving SFs may vary across contexts. Previous research, however, suggests that to lay people the 
underlying meaning of SFs is similar regardless of the setting (Daack-Hirsch et al., 2013); hence, 
needs for empathetic expert support and access to care can be expected to be comparable across 
contexts.  
Finally, participants of this study were self-selected, primarily female, middle-aged, and possibly 
more interested in health risk management than the average citizen. Children and young adults were 
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seen as vulnerable to receiving SFs, but it should be noted that most participants were middle-aged 
themselves. Diversity of educational and professional backgrounds, however, resulted in broad 
variety of points of views on receiving SFs. 
Conclusions  
Results of the current study suggest potential for shock and prolonged worry after receiving genetic 
SFs linked to serious but actionable diseases, and that the lack of available expert support or timely 
referral to treatment are likely to increase this distress. Discussion around SFs needs to concern not 
only which findings to report, but also how healthcare systems need to prepare for providing timely 
access to preventive care and support for individuals and families. Procedures that follow reporting 
SFs need to be carefully formulated and communicated to patients/research participants, in order to 
ensure that people will not feel left alone to deal with SFs. Participants of the current study wished 
for expert support to make informed, autonomous decisions regarding their own and their family 
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Table 1. Online writing task. 
Please read the following and write down what You would think and do in the situation. 
---------- 
Dear Madam/Sir,  
You have been to a university hospital, where your blood sample was collected to examine a 
disease, and the sample was used to sequence your whole genome (genes were spelled out 
letter by letter). When genes are spelled out letter by letter, it is possible that also other 
health related genetic mutations are found. 
Before giving the blood sample, You signed a consent form stating that you can be 
contacted if also other health related findings were found during the examination.  
Your recently analyzed results indicate [susceptibility to LS, LFS, LQTS, or FH]. 
[Brief description of the disease, its inheritance and relevance to family members, and 
preventive methods.] 
[Recommendations to contact genetics clinic of the university hospital for LS and LFS / 
laboratory of the healthcare center for LQTS and FH.] 
If You have any questions, you can contact the healthcare personnel below. 
[Hypothetical contact details for personnel at the university hospital] 
----------- 
Please imagine this situation and write down what You would think and do in this situation. 
 (Open responses) 
------------- 
We ask you to imagine being in the situation  described in the letter until you come to the 
focus group discussion, and to think about  how you would act, after first reactions, to 








Table 2. Description of diseases at study focus. 
                                                 
1 Youngblom E, Pariani M, Knowles JW. Familial Hypercholesterolemia. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. Seattle (WA): University of Washington, Seattle; 1993-2017. 
January 2, 2014; Last Update: December 8, 2016. 
2 Alders M and  Christiaans I. Long QT syndrome.In: Pagon RA, Adam MP, Ardinger HH, et al., editors. Seattle (WA): University of Washington, Seattle; 1993-2017. February 20, 2003; Last 
Update: June 18, 2015. 
3 Kohlmann W and  Gruber SB. Lynch Syndrome. Lynch Syndrome. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. Seattle (WA): University of Washington, Seattle; 1993-2017. 
2004; Last Update: May 22, 2014. 
4 Schneider K, Zelley K, Nichols KE, Garber J. Li-Fraumeni Syndrome. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Ledbetter N, Mefford HC, 
Smith RJH, Stephens K, editors. GeneReviews®[Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017. 1999 Jan 19 [updated 2013 Apr 11]. 
Disease; abbreviation Disease OMIM 
number 
Description Mode of 
inheritance  









leading to coronary 











Medication to lower cholesterol 
(statins) and other preventive 
measures: cessation of smoking, 
increased physical activity, reduced 
intake of saturated fats and increased 
intake of daily soluble fibre 













Lynch syndrome;  
LS3 






44−61 years CRC 
48−62 years EMC 
 













Childhood , early 
adulthood 
(1) Children and adults undergo 
comprehensive annual physical 
examination. 
(2) Women undergo breast cancer 
monitoring, with annual breast MRI 
and twice annual clinical breast 
examination beginning at age 20−25 
years. 
